| Literature DB >> 30085400 |
Caragh P Stapleton1, Kelly A Birdwell2, Amy Jayne McKnight3, Alexander P Maxwell3, Patrick B Mark4, M Lee Sanders5, Fiona A Chapman4, Jessica van Setten6, Paul J Phelan7, Claire Kennedy8, Alan Jardine4, Jamie P Traynor4, Brendan Keating9, Peter J Conlon8,10, Gianpiero L Cavalleri1.
Abstract
Renal transplant recipients have an increased risk of non-melanoma skin cancer (NMSC) compared to in the general population. Here, we show polygenic risk scores (PRS) calculated from genome-wide association studies (GWAS) of NMSC in a general, nontransplant setting, can predict risk of, and time to posttransplant skin cancer. Genetic variants, reaching predefined P-value thresholds were chosen from published squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) nontransplant GWAS. Using these GWAS, BCC and SCC PRS were calculated for each sample across three European ancestry renal transplant cohorts (n = 889) and tested as predictors of case:control status and time to NMSC posttransplant. BCC PRS calculated at P-value threshold 1 × 10-5 was the most significant predictor of case:control status of NMSC posttransplant (OR = 1.61; adjusted P = .0022; AUC [full model adjusted for clinical predictors and PRS] = 0.81). SCC PRS at P-value threshold 1 × 10-5 was the most significant predictor of time to posttransplant NMSC (adjusted P = 9.39 × 10-7 ; HR = 1.41, concordance [full model] = 0.74). PRS of nontransplant NMSC is predictive of case:control status and time to NMSC posttransplant. These results are relevant to how genomics can risk stratify patients to help develop personalized treatment regimens.Entities:
Keywords: basic research/science; complication: malignant; dermatology; genetics; genomics; kidney transplantation/nephrology; risk assessment/risk stratification; side effects
Mesh:
Substances:
Year: 2018 PMID: 30085400 PMCID: PMC6367067 DOI: 10.1111/ajt.15057
Source DB: PubMed Journal: Am J Transplant ISSN: 1600-6135 Impact factor: 8.086